Moolec ScienceMLEC -4.80%46 Gross Margin % is 24.38% as of Dec. 2025, which is 37% below its 10-year median of 38.45. GuruFocus rates MLEC with a GF Score™ of 46/100 and a GF Value™ of $84.84 (Possible Value Trap). The stock has 9 warning signs investors should review. Among 738 Biotechnology companies, Moolec Science ranks worse than 71.27% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Moolec Science had a gross margin of 24.38% for the quarter that ended in Dec. 2025 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Moolec Science Gross Margin % Related Terms
Moolec Science Gross Margin % Historical Data
* Premium members only.
The historical data trend for Moolec Science's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MLEC vs RVPH, CDIO, DRMA: Gross Margin % Comparison
For the Biotechnology subindustry, Moolec Science's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moolec Science Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Moolec Science's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Moolec Science's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Moolec Science (MLEC) has a Gross Margin % of 24.38% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Moolec Science and its competitors. This is 37% below median its historical median of 38.45. Over the past decade, Moolec Science's Gross Margin % has ranged from 37.49 to 42.58. According to the industry distribution chart, Moolec Science ranks #526 out of 738 companies in the Biotechnology industry, placing it in the top 71.3%.
Is Moolec Science's Gross Margin % too high?
Moolec Science's current Gross Margin % of 24.38% is 37% below median its 10-year median of 38.45. Over the past 10 years, this metric has ranged from a low of 37.49 to a high of 42.58. The Biotechnology industry median Gross Margin % is 60.94. Moolec Science's value of 24.38% is 60% below this industry median. Based on the distribution chart, Moolec Science ranks #526 out of 738 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Moolec Science has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Moolec Science's Gross Margin % compare to RVPH and CDIO?
According to the Biotechnology industry distribution chart, Moolec Science ranks #526 out of 738 companies for Gross Margin %. This places Moolec Science in the lower half of its industry. The industry median Gross Margin % is 60.94. Moolec Science's value of 24.38% is 60% below this benchmark. Historically, Moolec Science's own Gross Margin % has ranged from 37.49 to 42.58 over the past decade. While the company's 10-year median is 38.45 vs. the industry median of 60.94, Moolec Science has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.94, based on 738 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Moolec Science's current Gross Margin % of 24.38% is 60% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Moolec Science and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Moolec Science's current Gross Margin % is 24.38%, which is 37% below median its own 10-year median of 38.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moolec Science stock overvalued right now?
Based on GuruFocus' analysis, Moolec Science (MLEC) is currently considered Possible Value Trap. The stock's GF Value™ is $84.84, compared to a current price of $7.62 — trading 91% below its estimated fair value. The current Gross Margin % is 24.38%, which is 37% below median its 10-year median of 38.45 and 60% below the Biotechnology industry median of 60.94. Moolec Science's overall GF Score™ is 46/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Moolec Science (MLEC), the current Gross Margin % is 24.38% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Moolec Science (MLEC) Overvalued in 2026?
Based on GuruFocus' analysis, Moolec Science stock appears to be undervalued.
The current stock price of $7.62 is trading 91% below its estimated GF Value™ of $84.84.
GuruFocus considers Moolec Science to be Possible Value Trap.
Key valuation signals for MLEC:
Gross Margin %: 24.38% (37% below median its 10-year median of 38.45)
GF Value™: $84.84 vs. price of $7.62 (91% below fair value)
Industry Position: 60% below the Biotechnology median (#526 of 738)
No single metric tells the full story. See the MLEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline, such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's maximum revenues from operations in Argentina.
46GF Score
Get the complete analysis for MLEC
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLEC has been successfully added to your 
